Immune-based therapies for cytomegalovirus infection (Q37773240)

22 August 2017

1 reference

title

Immune-based therapies for cytomegalovirus infection (English)

1 reference

22 August 2017

0 references

Raymund R Razonable

1

1 reference

22 August 2017

1 January 2010

1 reference

22 August 2017

1 reference

22 August 2017

2

1 reference

22 August 2017

1

1 reference

22 August 2017

117-130

1 reference

Cytomegalovirus seroepidemiology in an urban community of São Paulo, Brazil

22 August 2017

1 reference

Is there a change in cytomegalovirus seroepidemiology in Spain?

21 January 2018

1 reference

Incidence of cytomegalovirus infection among the general population and pregnant women in the United States.

21 January 2018

1 reference

Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2.

21 January 2018

1 reference

Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation

21 January 2018

1 reference

Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion.

21 January 2018

1 reference

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

21 January 2018

1 reference

Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts

21 January 2018

1 reference

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

21 January 2018

1 reference

Cytomegalovirus infection after liver transplantation: current concepts and challenges

21 January 2018

1 reference

Delayed-onset primary cytomegalovirus disease after liver transplantation

21 January 2018

1 reference

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation

21 January 2018

1 reference

Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients

21 January 2018

1 reference

Clinical features and outcomes of cytomegalovirus retinitis after transplantation

21 January 2018

1 reference

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

21 January 2018

1 reference

Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies

21 January 2018

1 reference

Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

21 January 2018

1 reference

Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.

21 January 2018

1 reference

Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America

21 January 2018

1 reference

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients

21 January 2018

1 reference

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group

21 January 2018

1 reference

Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.

21 January 2018

1 reference

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants

21 January 2018

1 reference

Development of a cytomegalovirus vaccine: lessons from recent clinical trials

21 January 2018

1 reference

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial

21 January 2018

1 reference

A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

21 January 2018

1 reference

Vaccine prevention of maternal cytomegalovirus infection

21 January 2018

1 reference

Entry route of HCMV into endothelial cells

21 January 2018

1 reference

Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells

21 January 2018

1 reference

Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation

21 January 2018

1 reference

Combined prophylaxis decreases incidence of CMV-associated pneumonia after lung transplantation.

21 January 2018

1 reference

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

21 January 2018

1 reference

CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model

21 January 2018

1 reference

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

21 January 2018

1 reference

Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation

21 January 2018

1 reference

Positive selection and expansion of cytomegalovirus-specific CD4 and CD8 T cells in sealed systems: potential applications for adoptive cellular immunoreconstitution

21 January 2018

1 reference

Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy

21 January 2018

1 reference

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

21 January 2018

1 reference

Combined CMV Prophylaxis Improves Outcome and Reduces the Risk for Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.09.82

1 reference

22 August 2017

1 reference

PubMed ID

20635892